Adoptive cellular therapy for chronic lymphocytic leukemia and B cell malignancies. CARs and more

详细信息    查看全文

• 作者：Januario E. Castro^a ; ^b ; ^{jecastro@ucsd.edu" class="auth_mail" title="E-mail the corresponding author} ; Thomas J. Kipps^a ; ^b
• 关键词：CLL ; B cell malignancy ; Adoptive cellular therapy ; Cellular engineering
• 刊名：Best Practice Research Clinical Haematology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：29
• 期：1
• 页码：15-29
• 全文大小：312 K

文摘

Treatment of patients with chronic lymphocytic leukemia and other B cell malignancies is evolving very rapidly. We have observed the quick transition during the last couple of years, from chemo-immunotherapy based treatments to oral targeted therapies based on B cell receptor signaling and Bcl-2 inhibitors, as well as the increasing use of second generation glyco-engineered antibodies.

The next wave of revolution in the treatment for this conditions is approaching and it will be based on strategies that harness the power of the immune system to fight cancer. In the center of this biotechnological revolution is cellular engineering, the field that had made possible to redirect the immune system effector cells to achieve a more effective and targeted adoptive cellular therapy.

In this chapter, we will review the historical context of these scientific developments, the most recent basic and clinical research in the field and some opinions regarding the future of adoptive cellular therapy in CLL and other B cell malignancies.